In Reply: Dr Finucane points out that the safety profiles of celecoxib and standard NSAIDs are roughly comparable at 12 months. It is unclear why gastric ulcerative changes would differ at 6 or 12 months or whether the same can be said for rofcoxib, another COX-2 inhibitor.1 Nonetheless, physicians should consider the drugs' equivalent therapeutic benefits and cost differentials when chosing a specific NSAID for individual patients.
Lonner JH. Pain Management in Patients With Osteoarthritis—Reply. JAMA. 2003;290(1):36. doi:10.1001/jama.290.1.36-c
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: